NCT00789997View on ClinicalTrials.gov

TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

October 31, 2011

Conditions
COPD Exacerbation
Interventions
DRUG

Prednisone

prednisone 40 mg daily for 10 days or placebo prednisone

DRUG

Etanercept

etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection

DRUG

levofloxacin

Levofloxacin 750 mg daily for 10 days.

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER